Drug Approval | September 22, 2024
Briefs: Biocon, Aarti Drugs and Glenmark Pharmaceuticals
Glenmark Pharmaceuticals Limited has informed that the USFDA has issued Form 483 with zero observations
Glenmark Pharmaceuticals Limited has informed that the USFDA has issued Form 483 with zero observations
This strong performance was primarily on account of a one-time gain from the strategic collaboration between Biocon Biologics and Eris Lifesciences.
The results are an outcome of the company's focus on sustainable and profitable growth and reflects all the hard work and focus teams have put in over the years
Both departments will be equipped with specialized professionals and state-of-the-art facilities ensuring the highest standards of care
Integrated Disease Surveillance Programme (IDSP) strengthened to improve disease surveillance and rapid data reporting
The academy has secured partnerships with 15 esteemed hospitals
The initiative aimed to reach and support individuals suffering from epilepsy through early detection and effective disease management
Aster CMI Hospital has successfully implemented several key digital health initiatives contributing to this accreditation
Renews GMP certifications for India and Malaysia sites
Achira is engaged in development and commercialization of PoC medical test kits in India
Subscribe To Our Newsletter & Stay Updated
